Shi-Yi Wang, MD, PhD
Senior Research Scientist in EpidemiologyDownloadHi-Res Photo
Cards
Contact Info
About
Titles
Senior Research Scientist in Epidemiology
Biography
Dr. Wang is an Associate Professor at the Yale School of Public Health, faculty member of Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, and faculty member of Public Health Modeling Concentration, Yale School of Public Health. His primary interests focus on outcomes research and decision science. He is interested in combining systematic literature reviews, secondary data analyses, and simulation modeling to examine issues that are critical to clinicians and policy makers’ decision making. He has been working on several breast cancer projects, including an evaluation of preoperative breast MRI, development of an individualized decision aid to help radiotherapy decision-making, and assessment of sentinel lymph node biopsy for patients with ductal carcinoma in situ. He is also evaluating end-of-life care quality. He has served as the primary investigator or co-investigator in several projects (funded by Yale Cancer Center, AHRQ, NCI, ACS, and PCORI).
Last Updated on April 07, 2025.
Appointments
Chronic Disease Epidemiology
Senior Research ScientistPrimaryChronic Disease Epidemiology
LecturerSecondary
Other Departments & Organizations
Education & Training
- PhD
- University of Minnesota (2012)
- MD
- Taipei Medical College (1992)
Research
Overview
Medical Research Interests
Breast Neoplasms; Terminal Care
Public Health Interests
Health Care Quality, Efficiency; Modeling; Global Health; Aging; End-of-life Care; Cancer
ORCID
0000-0002-3294-5784
Research at a Glance
Yale Co-Authors
Frequent collaborators of Shi-Yi Wang's published research.
Publications Timeline
A big-picture view of Shi-Yi Wang's research output by year.
Research Interests
Research topics Shi-Yi Wang is interested in exploring.
Cary Gross, MD
Xiaomei Ma, PhD
Natalia Kunst, PhD
Michael S. Leapman, MD, MHS
Michaela Dinan, PhD
Isaac Y. Kim, MD, PhD, MBA
91Publications
3,155Citations
Breast Neoplasms
Terminal Care
Publications
2025
Biomarker-Specific Survival and Medication Cost for Patients With Non–Small Cell Lung Cancer
Tan J, Yang S, Dinan M, Chiang A, Gross C, Wang S. Biomarker-Specific Survival and Medication Cost for Patients With Non–Small Cell Lung Cancer. JAMA Network Open 2025, 8: e2514519. PMID: 40493365, PMCID: PMC12152704, DOI: 10.1001/jamanetworkopen.2025.14519.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerEGFR variationPD-L1ALK rearrangementCell lung cancerDriver alterationsMedical costsLung cancerCohort studyProgrammed cell death 1 ligand 1Cell death 1 ligand 1Biomarker statusMedian overall survivalRetrospective cohort studyLower medical costsOverall survivalTargeted therapyNon-smallPatient cohortMonthly medical costsFollow-upStudy cohortBiomarker testingAssociated with higher costsAdoption of Broad Genomic Profiling in Patients With Cancer
Wang X, Rothen J, Huang S, Long J, Soulos P, Goldberg S, Mamtani R, Presley C, Kunst N, Ma S, Wang S, Gross C, Dinan M. Adoption of Broad Genomic Profiling in Patients With Cancer. JAMA Oncology 2025, 11: 666-668. PMID: 40244595, PMCID: PMC12006912, DOI: 10.1001/jamaoncol.2025.0499.Peer-Reviewed Original ResearchAltmetricUse of targeted therapy in patients with advanced non-small cell lung cancer in response to broad genomic profiling.
Wang X, Long J, Rothen J, Huang S, Soulos P, Robinson T, Presley C, Goldberg S, Mamtani R, Ma S, Wang S, Kunst N, Dinan M, Gross C. Use of targeted therapy in patients with advanced non-small cell lung cancer in response to broad genomic profiling. Journal Of Clinical Oncology 2025, 43: 11155-11155. DOI: 10.1200/jco.2025.43.16_suppl.11155.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerCell lung cancerTargeted therapyLung cancerTargetable alterationsGenomic profilingUsefulness of targeted therapyUS cancer clinicsFirst-line treatmentCohort of patientsClinico-genomic databaseNCCN GuidelinesIdentified patientsPatient populationFDA approvalTreatment selectionPatientsCancer clinicClinical guidelinesTherapyCancerLimited dataTT useFDA approval statusAssociation between patient demographics and smoldering multiple myeloma progression to multiple myeloma: A SEER-Medicare data analysis
Theprungsirikul P, Wang R, Ahmad I, Neparidze N, Ma X, Chang S, Wang S. Association between patient demographics and smoldering multiple myeloma progression to multiple myeloma: A SEER-Medicare data analysis. Clinical Lymphoma Myeloma & Leukemia 2025 DOI: 10.1016/j.clml.2025.06.016.Peer-Reviewed Original ResearchConceptsSmoldering multiple myelomaSmoldering multiple myeloma patientsMultiple myelomaPatient demographicsProgression to multiple myelomaSymptomatic multiple myelomaDevelopment of hypercalcemiaCox proportional hazards modelsRisk stratification modelConfidence intervalsNon-cancer controlsEstimate hazard ratiosProportional hazards modelNon-cancer patientsSymptomatic MMRandom sample of Medicare beneficiariesSMM patientsRenal failureAnalyzed SurveillanceSEER-MedicareNatural history modelHazard ratioBone diseasePatientsSample of Medicare beneficiariesRisk and predictors of late second primary malignancies in long-term breast, prostate, colon, and rectal cancer survivors.
Kwaramba T, Westvold S, Long J, Hyslop T, Silber A, Lustberg M, Wang S, Leapman M, Leeds I, Cecchini M, Spees L, Wheeler S, Gross C, Dinan M. Risk and predictors of late second primary malignancies in long-term breast, prostate, colon, and rectal cancer survivors. Journal Of Clinical Oncology 2025, 43: 1642-1642. DOI: 10.1200/jco.2025.43.16_suppl.1642.Peer-Reviewed Original ResearchConceptsSurvivors of breastRectal cancer survivorsCancer survivorsYears post-diagnosisPost-diagnosisOlder survivorsScreen-detectedSEER-MedicareLong-term cancer survivorsNon-screened cancersLong-term breastStage I-III cancerProstate cancer survivorsIndex cancer diagnosisContinuous Medicare Parts ASEER-Medicare dataModifiable risk factorsMedicare Part ADiagnosis of SPMSurvivorship careSEER-Medicare databaseSurvivorship cohortScreening guidelinesAssociated with shorter timeIndex cancerHigh-Deductible Health Plans and Out-of-Pocket Health Care Costs Among Younger Patients With Multiple Myeloma.
Fiala M, Ji M, Slade M, Huber J, Shih Y, Wang M, Colditz G, Wang S, Vij R, Chang S. High-Deductible Health Plans and Out-of-Pocket Health Care Costs Among Younger Patients With Multiple Myeloma. JCO Oncology Practice 2025, op2400978. PMID: 40354593, DOI: 10.1200/op-24-00978.Peer-Reviewed Original ResearchAltmetricConceptsStem-cell transplantationMultiple myelomaTreatment initiationHigh-deductible health plan enrollmentHigh-deductible health plansTransplant receiptShorter time to treatment initiationTime to treatment initiationOOP costsHealth Insurance DatabaseAssociated with delayStatistically significant differenceHealth plansPlan enrolleesOut-of-pocket health care costsYounger patientsOut-of-pocket (OOP) costsCox regressionPrimary outcomeMultivariate analysisSecondary outcomesInsurance DatabasePatientsTotal health careHealth care costsBPI25-005: Molecular Biomarker Testing Patterns and Turn-Around Time in US Patients With Advanced Non-Small Cell Lung Cancer.
Wang X, Lee D, Yang S, Li Y, Soulos P, Gross C, Wang S, Chiang A. BPI25-005: Molecular Biomarker Testing Patterns and Turn-Around Time in US Patients With Advanced Non-Small Cell Lung Cancer. Journal Of The National Comprehensive Cancer Network 2025, 23 PMID: 40154384, DOI: 10.6004/jnccn.2024.7178.Peer-Reviewed Original ResearchBPI25-017: A Novel Integrated Classification Schema for Molecular Findings by Potential Clinical Actionability: A Tool for Assessment of Real-World Cancer Care in the Targeted Therapy Era.
Wang X, Long J, Rothen J, Soulos P, Robinson T, Presley C, Goldberg S, Mamtani R, Wang S, Kunst N, Ma S, Huang S, Gross C, Dinan M. BPI25-017: A Novel Integrated Classification Schema for Molecular Findings by Potential Clinical Actionability: A Tool for Assessment of Real-World Cancer Care in the Targeted Therapy Era. Journal Of The National Comprehensive Cancer Network 2025, 23 PMID: 40154428, DOI: 10.6004/jnccn.2024.7205.Peer-Reviewed Original ResearchPersonalized frailty risk assessment in long-term survivors of colorectal cancer.
Forman R, Westvold S, Long J, Fan J, Hyslop T, Yasin F, Conlin K, Jacobson S, Silber A, Wang S, Leapman M, Leeds I, Cecchini M, Spees L, Wheeler S, Gross C, Oeffinger K, Dinan M. Personalized frailty risk assessment in long-term survivors of colorectal cancer. Journal Of Clinical Oncology 2025, 43: 65-65. DOI: 10.1200/jco.2025.43.4_suppl.65.Peer-Reviewed Original ResearchConceptsRectal cancer survivorsCancer survivorsElixhauser Comorbidity IndexLong-term survivors of colorectal cancerSurvivors of colorectal cancerClinical prediction modelStage I-III colonCancer diagnosisGastrointestinal cancer survivorsYear 4Area-level povertyAssociated with reduced qualityRisk of frailtyProportion of residentsOnset of frailtyPredictors of frailtyFederal poverty lineIncreased risk of deathAdministrative claims codesSurvivorship managementRisk of deathRetrospective cohort studyAssociated with shorter timePatient raceSevere frailty
2024
Associations Between Patient Characteristics and Progression to Multiple Myeloma Among Patients With Monoclonal Gammopathy of Undetermined Significance: A Systematic Review
Li Y, Hsu S, Wang R, Theprungsirikul P, Neparidze N, Chang S, Wang S. Associations Between Patient Characteristics and Progression to Multiple Myeloma Among Patients With Monoclonal Gammopathy of Undetermined Significance: A Systematic Review. Clinical Lymphoma Myeloma & Leukemia 2024, 25: e222-e231. PMID: 39730300, PMCID: PMC11911095, DOI: 10.1016/j.clml.2024.12.006.Peer-Reviewed Original ResearchCitationsAltmetricConceptsProgression to MMMultiple myelomaNewcastle-Ottawa ScaleMonoclonal gammopathyRisk of progression to MMIncreased riskProgression to multiple myelomaRisk estimatesHigher body mass indexPre-malignant conditionBody mass indexRandom-effects modelMass indexCohort studyPatient characteristicsFemale sexMale genderMethodological qualityNewcastle-OttawaBlack raceRisk ratioMGUSRisk factorsPublication biasSystematic review
Academic Achievements & Community Involvement
Honors
honor The Population Science Research Prize
01/31/2017Other AwardYale Cancer CenterDetailsUnited Stateshonor The Distinguished Student Mentor Award
06/30/2016Other AwardYale School of Public HealthDetailsUnited States
News
News
- May 06, 2025
Genetic Test Underused in Cancer Care
- August 07, 2023
Screening Mammograms Carry Risks for Older Women, Study Finds
- May 05, 2023
Becca Levy and the Fight Against Ageism
- March 05, 2023
Improving Care of Patients Receiving Advanced Cancer Treatment
Get In Touch
Contacts
Email
Academic Office Number
Locations
60 College Street
Academic Office
Ste 432
New Haven, CT 06510